[go: up one dir, main page]

AR116024A1 - Métodos de tratamiento de enfermedades neurodegenerativas - Google Patents

Métodos de tratamiento de enfermedades neurodegenerativas

Info

Publication number
AR116024A1
AR116024A1 ARP190102440A ARP190102440A AR116024A1 AR 116024 A1 AR116024 A1 AR 116024A1 AR P190102440 A ARP190102440 A AR P190102440A AR P190102440 A ARP190102440 A AR P190102440A AR 116024 A1 AR116024 A1 AR 116024A1
Authority
AR
Argentina
Prior art keywords
methods
treatment
neurodegenerative diseases
dyrk1a
ask1
Prior art date
Application number
ARP190102440A
Other languages
English (en)
Inventor
Samuel David Brown
Kathleen Ann Elias
Artur Plonowski
Neil Dwayne Mdonnell
Terence Graham Porter
Original Assignee
Seal Rock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seal Rock Therapeutics Inc filed Critical Seal Rock Therapeutics Inc
Publication of AR116024A1 publication Critical patent/AR116024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos de tratamiento o prevención de enfermedades, trastornos o condiciones relacionadas con ASK1 o DYRK1A, que comprenden administrar a un sujeto que lo necesita un inhibidor dual de ASK1 o DYRK1A o sus sales y solvatos farmacéuticamente aceptables.
ARP190102440A 2018-08-29 2019-08-27 Métodos de tratamiento de enfermedades neurodegenerativas AR116024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862724574P 2018-08-29 2018-08-29

Publications (1)

Publication Number Publication Date
AR116024A1 true AR116024A1 (es) 2021-03-25

Family

ID=69644584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102440A AR116024A1 (es) 2018-08-29 2019-08-27 Métodos de tratamiento de enfermedades neurodegenerativas

Country Status (4)

Country Link
US (1) US20210213006A1 (es)
AR (1) AR116024A1 (es)
TW (1) TW202024020A (es)
WO (1) WO2020046975A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240148835A1 (en) * 2021-01-28 2024-05-09 University Of Florida Research Foundation, Incorporated Treating disorders associated with dyrk1a dysfunction
KR20250044687A (ko) * 2022-07-20 2025-04-01 씰 록 테라퓨틱스, 인크. Ask1 억제제를 이용한 장기 질환 또는 장애 치료 방법
CN117551093B (zh) * 2023-11-14 2024-06-18 山东天锐医药科技有限公司 马来酸阿伐曲泊帕起始原料4-(4-氯-2-噻吩基)-2-噻唑胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
US8293747B2 (en) * 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
US8344160B2 (en) * 2008-10-08 2013-01-01 Bristol-Myers Squibb Company Pyrrolone melanin concentrating hormone receptor-1 antagonists
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
EP3735404B1 (en) * 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof

Also Published As

Publication number Publication date
TW202024020A (zh) 2020-07-01
US20210213006A1 (en) 2021-07-15
WO2020046975A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2021013788A (es) Dosificación del inhibidor de kras para el tratamiento de cánceres.
MX2021005154A (es) 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2020000911A1 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
MX2017005875A (es) Metodos para tratar enfermedades oculares.
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
ECSP21016032A (es) Inhibidores de la interacción proteína-proteína keap1-nrf2
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
PH12020550532A1 (en) Agent for preventing or treating small intestinal injury induced by non-steroidal anti-inflammatory drug and proton pump inhibitor
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131

Legal Events

Date Code Title Description
FB Suspension of granting procedure